SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-24-006061 to Apollomics Inc. (APLM, APLMW) (CIK 0001944885) (APLM)

Apollomics Inc. (APLM, APLMW) (CIK 0001944885)
Date: May 24, 2024 · CIK: 0001944885 · Accession: 0000000000-24-006061

AI Filing Summary & Sentiment

File numbers found in text: 333-279549

Date
May 24, 2024
Author
Not clearly detected
Form
UPLOAD
Company
Apollomics Inc. (APLM, APLMW) (CIK 0001944885)

Letter

United States securities and exchange commission logo May 24, 2024 Sanjeev Redkar President Apollomics Inc. 989 E. Hillsdale Blvd., Suite 220 Foster City, CA 94404 Re:Apollomics Inc. Registration Statement on Form F-3 Filed May 20, 2024 File No. 333-279549 Dear Sanjeev Redkar: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Ryan Coombs

Show Raw Text
United States securities and exchange commission logo
May 24, 2024
Sanjeev Redkar
President
Apollomics Inc.
989 E. Hillsdale Blvd., Suite 220
Foster City, CA 94404
Re:Apollomics Inc.
Registration Statement on Form F-3
Filed May 20, 2024
File No. 333-279549
Dear Sanjeev Redkar:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Ryan Coombs